enGene Holdings Inc. (NASDAQ:ENGN) Receives $12.68 Average Price Target from Analysts

Posted by on May 20th, 2026

Shares of enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) have received a consensus recommendation of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $12.6818.

Several analysts have recently commented on the stock. Guggenheim lowered shares of enGene from a “buy” rating to a “neutral” rating in a research report on Thursday, May 7th. UBS Group reduced their price target on shares of enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Leerink Partners lowered shares of enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price target on the stock. in a research report on Friday, May 8th. Jefferies Financial Group began coverage on shares of enGene in a research report on Friday, January 30th. They set a “buy” rating and a $28.00 price target on the stock. Finally, Piper Sandler downgraded shares of enGene from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $7.00 to $4.00 in a report on Friday, May 8th.

Read Our Latest Stock Report on enGene

Institutional Trading of enGene

Several institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC increased its holdings in enGene by 179.8% in the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock valued at $52,998,000 after purchasing an additional 3,771,840 shares during the last quarter. Siren L.L.C. increased its holdings in enGene by 57.5% in the 1st quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock valued at $35,774,000 after purchasing an additional 1,916,895 shares during the last quarter. Cormorant Asset Management LP increased its holdings in enGene by 72.1% in the 4th quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after purchasing an additional 1,676,405 shares during the last quarter. Blue Owl Capital Holdings LP increased its holdings in enGene by 2.5% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,360,937 shares of the company’s stock valued at $30,349,000 after purchasing an additional 82,831 shares during the last quarter. Finally, Braidwell LP increased its holdings in enGene by 38.2% in the 4th quarter. Braidwell LP now owns 3,131,319 shares of the company’s stock valued at $28,276,000 after purchasing an additional 865,000 shares during the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Stock Down 2.5%

ENGN stock opened at $1.53 on Friday. The firm has a market cap of $102.49 million, a PE ratio of -0.68 and a beta of -0.02. The company has a debt-to-equity ratio of 0.09, a quick ratio of 11.75 and a current ratio of 11.75. The firm’s 50 day moving average price is $6.31 and its 200-day moving average price is $7.93. enGene has a one year low of $1.40 and a one year high of $12.25.

enGene (NASDAQ:ENGN – Get Free Report) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.11. On average, equities research analysts anticipate that enGene will post -2.06 EPS for the current year.

enGene Company Profile

(Get Free Report)

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Read More

Analyst Recommendations for enGene (NASDAQ:ENGN)

Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.